FDA Panel Supports First mRNA-Based Flu Vaccine for Approval
A U.S. Food and Drug Administration (FDA) advisory panel has recommended approval of a new flu vaccine developed using mRNA technology, marking a major step forward in influenza prevention.
The vaccine, developed by Moderna and named mFluSiva, could become the first flu shot of its kind to reach the U.S. market.
Target Groups for the Vaccine
The FDA is currently reviewing the vaccine for:
- Adults aged 50 to 64 years (for full approval)
- Adults 65 years and older (for conditional authorization during ongoing studies)
The recommendation comes ahead of the upcoming winter flu season.
Expert Review and Findings
An independent FDA advisory committee reviewed clinical trial data and unanimously agreed that the vaccine’s benefits outweigh its potential risks for both age groups.
The final decision from the FDA is expected by early August 2026.
Why mRNA Flu Vaccines Matter
Influenza causes thousands of deaths each year in the United States, particularly among older adults. While traditional flu vaccines are already widely used, experts say mRNA technology could offer important advantages.
According to health specialists, mRNA vaccines:
- Can be developed more quickly than traditional vaccines
- May respond better to rapidly changing flu strains
- Could improve preparedness for future outbreaks
Expert Opinion
Health experts have highlighted that this technology may strengthen future pandemic and seasonal flu responses.
As one FDA adviser noted, the new approach could help improve readiness against evolving virus strains.
